Novel Immunotherapies for Myasthenia Gravis
Sruthi S Nair,Saiju Jacob
DOI: https://doi.org/10.2147/ITT.S377056
2023-04-04
ImmunoTargets and Therapy
Abstract:Sruthi S Nair, 1, 2 Saiju Jacob 1, 3 1 Department of Neurology, University Hospitals Birmingham, Birmingham, B15 2TH, UK; 2 Department of Neurology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, Kerala, India; 3 Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, UK Correspondence: Saiju Jacob, Consultant Neurologist, University Hospitals Birmingham, Edgbaston, Birmingham, B15 2TH, United Kingdom, Tel +44 0121 3716844, Fax +44 0121 4605300, Email Myasthenia gravis (MG), a prototype autoimmune neurological disease, had its therapy centred on corticosteroids, non-steroidal broad-spectrum immunotherapy and cholinesterase inhibitors for several decades. Treatment-refractory MG and long-term toxicities of the medications have been major concerns with the conventional therapies. Advances in the immunology and pathogenesis of MG have ushered in an era of newer therapies which are more specific and efficacious. Complement inhibitors and neonatal Fc receptor blockers target disease-specific pathogenic mechanisms linked to myasthenia and have proven their efficacy in pivotal clinical studies. B cell-depleting agents, specifically rituximab, have also emerged as useful for the treatment of severe MG. Many more biologicals are in the pipeline and in diverse stages of development. This review discusses the evidence for the novel therapies and the specific issues related to their clinical use. Keywords: myasthenia gravis, refractory myasthenia gravis, complement inhibitors, FcRn blocker, B cell depletion Myasthenia gravis (MG) is a chronic autoimmune disease of the neuromuscular junction (NMJ) clinically characterized by fatigable weakness of the ocular, limb and bulbar (speech, swallowing and respiratory) muscles. It is the most common acquired disease of the NMJ with an incidence of 0.3–2.8 per 100,000. 1 The burden of MG translates not only to disabling symptoms and increased hospitalizations, but also marked economic, social and emotional costs. 2 In MG, well-characterized antibodies have been identified against specific targets in the post-synaptic membrane. 3 Antibodies against acetylcholine receptor (AChR) are observed in a vast majority (nearly 85%) of generalized MG and antibodies against other components, namely muscle specific kinase (MuSK), lipoprotein related protein 4 (LRP4) and agrin have been reported in 5%, 2% and less than 1%, respectively in the remaining population. The remaining 5–8% with generalized disease have no currently attributable antigenic targets or antibodies and are referred to as seronegative MG. 4 The clinical severity of MG can range from mild ocular symptoms to frequent respiratory and bulbar crisis. In general, one-fifth of MG patients manifest only ocular weakness and are referred to as ocular MG whereas the rest, with a more diffuse weakness, are referred to as generalized MG (gMG). Ocular MG is less likely (approximately 50%) to have antibodies compared with gMG. 5 Distinctive clinical phenotypes have been recognized for each of the antibody subtypes of MG. 3 AChR antibody positive MG are classified into three subtypes: early onset ( 50 years) and thymoma associated MG (TAMG). Early onset MG has a female preponderance and strong associations with human leukocyte antigen (HLA) DR3-D8 and thymic follicular hyperplasia. In contrast, late onset MG often occurs in males, has no HLA association and may display anti-striational antibodies despite harbouring atrophic thymus. 4 Thymoma occurs in 15–30% of MG and is commonly associated with co-existing anti-ryanodine receptor and anti-titin antibodies. 6,7 MuSK-MG tends to present with a bulbar-dominant phenotype and usually does not have any significant thymic abnormalities. 8 The origin of the autoimmunity in MG has not been precisely elucidated, though genetic susceptibility and environmental triggers such as viral infections have been implicated. Pathological changes in the thymus are believed to play a pivotal role in the pathogenesis of AChR-MG. 9 The most accepted hypothesis centres around the failure of self-tolerance which occurs intrathymically in AChR-MG. Self-tolerance is ensured by a balance between immune cell generation and the timely removal of auto-reactive lymphocytes. The thymus is the primary organ for the maturation and differentiation of T cells. During their maturation, T cells including the T regulatory cells (Tregs) are exposed to thymic myoid cells which express AChR and autoimmune regulatory (AIRE) medullary epithelial cells. The latter play an important role in the clonal deletion of T cells sensitized to auto-antigens duri -Abstract Truncated-